Researchers explored the role of lipid-lowering drug targets in diabetic retinopathy using Mendelian randomization. Enhancement of peroxisome proliferator-activated receptor gamma (PPARG) was found to be associated with a lower risk of diabetic retinopathy, particularly in its early and proliferative stages, offering a potential therapeutic avenue. The researchers also analyzed causal relationships among lipid traits, drug targets, and full-course diabetic retinopathy. 

Source: British Journal of Ophthalmology